Program Description
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia. The current treatment approach with targeted, small-molecule inhibitors has provided improved survival outcomes and tolerability for patients with CLL in both the treatment-naïve and relapsed/refractory (R/R) settings. However, there remain challenges with current targeted treatment strategies, such as adherence to treatment guidelines, treatment-related adverse effects, and the impact on adherence. Oncology pharmacists have ample opportunity to promote awareness of guideline recommendations for treatment initiation and sequencing among all practitioners caring for patients with CLL to better inform therapeutic decisions. Managed care professionals have responsibilities to design protocols that address challenges affecting patient access to oral targeted therapies that balance cost-effectiveness and quality care. This program will review current treatment approaches for CLL as well as opportunities for managed care pharmacists to optimize coordination of care in the treatment of CLL with BTK inhibitors and combination therapy approaches. Considerations to the management and prevention of treatment-related adverse effects, medication adherence, and costs of care will also be addressed.
Target audience: Managed care pharmacists and oncology pharmacists
Type of activity: Application
Release date: June 20, 2023
Expiration date: August 20, 2023
Time to complete activity: 1.5 hours
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Apply patient and disease-specific factors, such as prognostic markers and clinical staging, in guiding treatment decisions for patients with CLL.
- Examine recent clinical updates and guideline-directed utilization of targeted therapies in the frontline management of CLL.
- Explore the best practices for managed care in preventing and mitigating adverse effects associated with small molecule inhibitors in CLL.
- Identify managed care considerations in the evolving treatment approaches for patients with CLL that evaluate the cost of care while improving patient outcomes.
Melani Rudisill, PharmD, BCOP
Clinical Pharmacist, Novant Health Forsyth Medical Center
Hematology/Transplant and Cellular Therapy
Winston-Salem, North Carolina
Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP
Clinical Oncology Pharmacy Manager
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-211-L01-P. The activity is available for CE credit through August 20, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, has the following financial relationships with commercial interests to disclose:
Consultant: Pfizer, Janssen, AstraZeneca
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Melani Rudisill, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Evelina Kolychev, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms